Novo Nordisk has successfully completed the acquisition of Novavax’s biologics manufacturing facility in Bohumil, Czech Republic, for $200 million. The deal, finalized on December 30, 2024, marks an important milestone for both companies and the pharmaceutical industry.
The 14,000-square-meter facility, which specializes in recombinant protein production, has been instrumental in manufacturing vaccines, including those for COVID-19. With approximately 150 skilled professionals employed at the site, the acquisition will bolster Novo Nordisk’s global manufacturing capabilities to meet increasing demand in the pharmaceutical sector.
For Novavax, this sale aligns with its strategic focus on streamlining operations and prioritizing its vaccine development pipeline. The transaction also highlights the Czech Republic’s growing importance as a hub for innovation and manufacturing in the global pharmaceutical and biotechnology industries.
This acquisition signifies a strong step forward for Novo Nordisk’s operations and reinforces the commitment to innovation, quality, and expanding global reach.
Zdroj: www.reuters.com
Zpracoval: tým zahraniční kanceláře CzechTrade Skandinávie